US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

CGEM Cullinan Therapeutics Inc

23.50

0.71 (3.12%)

31 May 2024 - Cerrado

Retrasado por 15 minutos

Form ARS - Annual Report to Security Holders

Cullinan Therapeutics (NASDAQ:CGEM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Haga Click aquí para más Gráficas Cullinan Therapeutics.

Cullinan Therapeutics (NASDAQ:CGEM)
Gráfica de Acción Histórica
De May 2023 a May 2024

Haga Click aquí para más Gráficas Cullinan Therapeutics.

Noticias sobre Cullinan Therapeutics Inc CGEM

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
Viernes 24 de Mayo 2024 (1 semana hace) • GlobeNewswire Inc.

Form 8-K - Current report
Jueves 23 de Mayo 2024 (1 semana hace) • Edgar (US Regulatory)

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Jueves 23 de Mayo 2024 (1 semana hace) • GlobeNewswire Inc.

Form S-3 - Registration statement under Securities Act of 1933
Jueves 16 de Mayo 2024 (2 semanas hace) • Edgar (US Regulatory)

Form ARS - Annual Report to Security Holders
Jueves 16 de Mayo 2024 (2 semanas hace) • Edgar (US Regulatory)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jueves 16 de Mayo 2024 (2 semanas hace) • Edgar (US Regulatory)

Form DEF 14A - Other definitive proxy statements
Jueves 16 de Mayo 2024 (2 semanas hace) • Edgar (US Regulatory)

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Miércoles 15 de Mayo 2024 (2 semanas hace) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 8 de Mayo 2024 (3 semanas hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Lunes 6 de Mayo 2024 (4 semanas hace) • Edgar (US Regulatory)

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
Lunes 29 de Abril 2024 (1 mes hace) • GlobeNewswire Inc.

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
Miércoles 24 de Abril 2024 (1 mes hace) • GlobeNewswire Inc.

Más de Cullinan Therapeutics Inc Artículos de Noticias

Cellectis Nom Eo 05

NLBNPIT1X005 20240920 500

NLBNPIT1TU13 20240621 160

NLBNPIT1Z620 20991231 46...

NLBNPIT1UJC6 20991231 15...

INTESA SANPAOLO

Ggr Covipe Renda Fundo I...

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones